William Blum, MD, is an associate professor of internal medicine at The Ohio State University (OSU) and James Cancer Hospital, in Columbus, Ohio, where he is Chief of the Acute Leukemia Section in the Division of Hematology. His research is focused on experimental therapeutics for acute leukemia, especially acute myeloid leukemia (AML). He serves as a cadre member of the Alliance Leukemia Core Committee and as Chair of the OSU Data and Safety Monitoring Committee. His main interest is advancing the care of older patients with AML, including development of alternatives to intensive induction chemotherapy.
The ideas and viewpoints expressed in this commentary are those of the author and do not necessarily represent any policy, position, or program of NCCN.